NCT04187690 is a NA clinical trial of Jin-shui Huan-xian granule in Idiopathic Pulmonary Fibrosis, sponsored by Henan University of Traditional Chinese Medicine.

Who is sponsoring NCT04187690?

NCT04187690 is sponsored by Henan University of Traditional Chinese Medicine.

What drugs are being tested in NCT04187690?

Interventions in NCT04187690: Jin-shui Huan-xian granule, Jin-shui Huan-xian granule placebo.

What condition does NCT04187690 study?

NCT04187690 studies Idiopathic Pulmonary Fibrosis.

Is NCT04187690 still recruiting?

NCT04187690 is currently status unknown. Last updated 18 August 2022.

Last reviewed 2022-08-18 · How we verify

NCT04187690

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Jin-shui Huan-xian Granule in the Treatment of IPF

Status unknown NA Last updated 18 August 2022

What this trial tests

NA trial testing Jin-shui Huan-xian granule in Idiopathic Pulmonary Fibrosis in 312 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
31 May 2023

30 July 2023

Quick facts

Lead sponsor	Henan University of Traditional Chinese Medicine
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	312
Start date	1 September 2020
Primary completion	31 May 2023
Estimated completion	30 July 2023
Sites	1 location across China

Drugs / interventions tested

Jin-shui Huan-xian granule — full drug profile →
Jin-shui Huan-xian granule placebo

Conditions studied

Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →

Sponsor

Henan University of Traditional Chinese Medicine

Who can join

Adults 40 to 85, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to evaluate the efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis (IPF), establish the treatment scheme, and obtain the high quality clinical evidences.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis.
Ma H, Wu X, Li Y, Xia Y. · · 2022 · cited 47× · PMID 35935869 · DOI 10.3389/fphar.2022.963054
Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.
Yang SG, Yu XQ, Li JS, Xie Y, et al · · 2022 · cited 4× · PMID 36056382 · DOI 10.1186/s13063-022-06684-0
Efficacy and Safety of Jin-Shui Huan-Xian Granule for Idiopathic Pulmonary Fibrosis: Study Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Yang S, Yu X, Li J, Xie Y, et al · · 2021 · DOI 10.21203/rs.3.rs-429927/v1

Verify or expand the search:

Other trials of Jin-shui Huan-xian granule

Trials testing the same drug.

NCT06914713 — Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF · NA · not yet recruiting

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting

Other Henan University of Traditional Chinese Medicine trials

Trials by the same sponsor.

NCT07352488 — Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome · NA · not yet recruiting
NCT07206745 — A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bact · NA · not yet recruiting
NCT07178392 — Disease-syndrome Characteristics of IPF · not yet recruiting
NCT07162870 — Idiopathic Pulmonary Fibrosis Cohort of TCM · not yet recruiting
NCT06914713 — Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04187690 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan University of Traditional Chinese Medicine
Last refreshed: 18 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04187690.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing